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Editorial on the Research Topic
Endocrine Forms of Hypertension: Clinical and Emerging Molecular Aspects
Secondary hypertension is responsible for about 5–20% of all hypertension cases depending
on the examined cohorts (1–3). In contrast with primary essential hypertension that can
only be treated, secondary hypertension often manifesting itself as resistant hypertension
includes potentially curable diseases (1–3). Research on endocrine diseases leading to secondary
hypertension is a progressive field, and better elucidating their pathophysiology and clinical
features, might pave the way for novel diagnostic modalities and treatments. The major
endocrine diseases as causes of hypertension include primary aldosteronism, hypercortisolism,
pheochromocytoma/paraganglioma, thyroid diseases, primary hyperparathyroidism,
and acromegaly.
In this Research Topic, we have compiled several articles on different issues of endocrine
secondary hypertension regarding both molecular and clinical features. Primary aldosteronism
is the most common endocrine cause of secondary hypertension affecting 5–13% of hypertensive
patients in different studies (4–6). Three articles are dedicated to its field in this Research Topic.
The study by Mohideen et al. was aimed at establishing the prevalence of KCNJ5 gene mutations
in APAs from a Malaysian cohort. The authors, by examining 54 APAs from a Malaysian cohort,
found that its prevalence was 31%, similarly as reported in Caucasians, however, with no prevalence
of mutants in females. KCNJ5 mutant and wild type APAs showed similar percentages of ZF- and
ZG- like cells, but KCNJ5 mutant APAs with a ZF-like profile tended to be associated with larger
APA. A higher expression of CYP11B2 was found in females, who also had adrenalectomy at a
younger age than males. An interesting hypothesis was provided by the Authors: since females had
often larger tumors, the phenotype previously associated with KCNJ5 mutant APAs could be the
phenotype of APAs from female patients, not the phenotype of all KCNJ5 mutant APAs.
In the original study by Decmann et al., circulating microRNAs belonging to the group of
non-coding RNA molecules (7, 8) are investigated as potential novel diagnostic tools for the
differentiation of the two major forms of primary aldosteronism i.e., bilateral adrenal hyperplasia
and unilateral adenoma. Three microRNAs were validated on a large cohort of samples to
be overexpressed in bilateral hyperplasia relative to the unilateral adenoma samples. Although
sensitivity and specificity values were not found to be high enough for clinical introduction
at present, this study presents a novel class of potential diagnostic markers for differentiating
subclasses of endocrine hypertension, but also underlines that primary aldosteronism could be
regarded as a spectrum disease.
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A comprehensive review on licorice-induced
pseudohyperaldosteronism is given by Sabbadin et al.,
who discussed its biochemical picture and the mechanisms
underlying the mineralocorticoid effect. Of interest, they
also discuss the potential therapeutic use of licorice related
to its anti-androgen and estrogen-like activity, mostly
exploited for treatment of polycystic ovary syndrome on
top of spironolactone, and the anti-inflammatory effects
of licorice, unveiling unfamiliar properties of an old
medicinal plant.
The pathophysiology and treatment of hypertension
in Cushing’s syndrome is discussed in the mini review
by Barbot et al.. Several relevant molecular mechanisms
are presented, and most notably antihypertensive and
also cortisol-lowering treatments are discussed. Clinically
relevant issues are also discussed in the mini review by
Canu et al. where the hypertension-related clinical picture,
genetics and treatment issues of pheochromocytoma
are presented.
Thyroid diseases are very frequent, but they less often affect
blood pressure values. A comprehensive view of the effects of
thyroid hormones on the cardiovascular system is provided by
Berta et al., who also discuss the genetic background that may
favor cardiovascular damage.
We hope that the reader will find this Research Topic
interesting, and the molecular and clinical issues covered by the
articles will be helpful in both research and clinical management
of secondary endocrine hypertension.
AUTHOR CONTRIBUTIONS
Both authors listed have made a substantial, direct and
intellectual contribution to the work, and approved it
for publication.
REFERENCES
1. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB,
Weissmann P. Hyperaldosteronism among black and white
subjects with resistant hypertension. Hypertension. (2002) 40:892–
6. doi: 10.1161/01.hyp.0000040261.30455.b6
2. Rossi GP, Seccia TM, Pessina AC. Secondary hypertension:
the ways of management. Curr Vasc Pharmacol. (2010) 8:753–
68. doi: 10.2174/157016110793563843
3. Wei FF, Zhang ZY, Huang QF, Staessen JA. Diagnosis and management of
resistant hypertension: state of the art. Nat Rev Nephrol. (2018) 14:428–
41. doi: 10.1038/s41581-018-0006-6
4. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri
C, et al. A prospective study of the prevalence of primary
aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. (2006)
48:2293–300. doi: 10.1016/j.jacc.2006.07.059
5. Käyser SC, Dekkers T, Groenewoud HJ, Van Der Wilt GJ, Carel Bakx J, Van
Der Wel MC, et al. Study heterogeneity and estimation of prevalence of
primary aldosteronism: a systematic review andmeta-regression analysis. J Clin
Endocrinol Metab. (2016) 101:2826–35. doi: 10.1210/jc.2016-1472
6. Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F,
Gaita F, et al. Cardiovascular events and target organ damage in
primary aldosteronism compared with essential hypertension: a
systematic review and meta-analysis. Lancet Diabetes Endocrinol. (2018)
6:41–50. doi: 10.1016/S2213-8587(17)30319-4
7. Igaz I, Igaz P. Tumor surveillance by circulating microRNAs: a hypothesis. Cell
Mol Life Sci. (2014) 71:4081–7. doi: 10.1007/s00018-014-1682-4
8. Igaz P. Circulating microRNAs in adrenal tumors. Curr Opin Endocrinol
Diabetes Obes. (2019) 26:155–9. doi: 10.1097/MED.0000000000000472
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2019 Igaz and Seccia. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and
the copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Endocrinology | www.frontiersin.org 2 December 2019 | Volume 10 | Article 857
